These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21460660)

  • 1. Cytomegalovirus and other infectious issues related to face transplantation: specific considerations, lessons learned, and future recommendations.
    Gordon CR; Avery RK; Abouhassan W; Siemionow M
    Plast Reconstr Surg; 2011 Apr; 127(4):1515-1523. PubMed ID: 21460660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the true significance of donor-related cytomegalovirus transmission in the setting of facial composite tissue allotransplantation?
    Gordon CR; Abouhassan W; Avery RK
    Transplant Proc; 2011 Nov; 43(9):3516-20. PubMed ID: 22099832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization, prophylaxis, and treatment of infectious complications in craniomaxillofacial and upper extremity allotransplantation: a multicenter perspective.
    Broyles JM; Alrakan M; Ensor CR; Khalifian S; Kotton CN; Avery RK; Brandacher G; Lee WPA; Gordon CR
    Plast Reconstr Surg; 2014 Apr; 133(4):543e-551e. PubMed ID: 24675206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
    Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
    Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a New Paradigm for Cytomegalovirus Disease Prevention in Mayo Clinic's First Face Transplant.
    Razonable RR; Amer H; Mardini S
    Mayo Clin Proc; 2019 Jan; 94(1):166-170. PubMed ID: 30611443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation.
    Alhefzi M; Aycart MA; Bueno EM; Kueckelhaus M; Fischer S; Snook RJ; Sharfuddin AA; Hadad I; Malla P; Amato AA; Pomahac B; Marty FM
    Transpl Infect Dis; 2016 Apr; 18(2):288-92. PubMed ID: 26910286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections following facial composite tissue allotransplantation--single center experience and review of the literature.
    Knoll BM; Hammond SP; Koo S; Issa NC; Tullius SG; Baden LR; Pomahac B; Marty FM
    Am J Transplant; 2013 Mar; 13(3):770-9. PubMed ID: 23279299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Institutional review board-based recommendations for medical institutions pursuing protocol approval for facial transplantation.
    Siemionow MZ; Gordon CR
    Plast Reconstr Surg; 2010 Oct; 126(4):1232-1239. PubMed ID: 20885245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.
    Couchoud C
    Cochrane Database Syst Rev; 2000; (2):CD001320. PubMed ID: 10796773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.
    Hodson EM; Jones CA; Webster AC; Strippoli GF; Barclay PG; Kable K; Vimalachandra D; Craig JC
    Lancet; 2005 Jun 18-24; 365(9477):2105-15. PubMed ID: 15964447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients.
    de la Torre-Cisneros J; Fariñas MC; Castón JJ; Aguado JM; Cantisán S; Carratalá J; Cervera C; Cisneros JM; Cordero E; Crespo-Leiro MG; Fortún J; Frauca E; Gavaldá J; Gil-Vernet S; Gurguí M; Len O; Lumbreras C; Marcos MÁ; Martín-Dávila P; Monforte V; Montejo M; Moreno A; Muñoz P; Navarro D; Pahissa A; Pérez JL; Rodriguez-Bernot A; Rumbao J; San Juan R; Santos F; Varo E; Zurbano F;
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):735-58. PubMed ID: 21925772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones C; Craig JC
    Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
    Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
    Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF; Hodson EM; Jones CJ; Craig JC
    Cochrane Database Syst Rev; 2006 Jan; (1):CD005133. PubMed ID: 16437521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The world's experience with facial transplantation: what have we learned thus far?
    Gordon CR; Siemionow M; Papay F; Pryor L; Gatherwright J; Kodish E; Paradis C; Coffman K; Mathes D; Schneeberger S; Losee J; Serletti JM; Hivelin M; Lantieri L; Zins JE
    Ann Plast Surg; 2009 Nov; 63(5):572-8. PubMed ID: 19806039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.
    Stratta RJ; Pietrangeli C; Baillie GM
    Pharmacotherapy; 2010 Feb; 30(2):144-57. PubMed ID: 20099989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.